Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/23/2024 | $6.00 | Perform → Outperform | Oppenheimer |
| 8/14/2024 | Buy → Neutral | Ladenburg Thalmann | |
| 4/16/2024 | $20.00 → $2.00 | Outperform → Neutral | Robert W. Baird |
| 4/15/2024 | $24.00 → $3.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 8/11/2023 | $14.00 → $9.00 | Outperform → Perform | Oppenheimer |
| 1/20/2023 | $23.00 | Outperform | RBC Capital Mkts |
| 12/20/2021 | $32.00 → $30.00 | Outperform | SVB Leerink |
Oppenheimer upgraded Marinus Pharmaceuticals from Perform to Outperform and set a new price target of $6.00
Ladenburg Thalmann downgraded Marinus Pharmaceuticals from Buy to Neutral
Robert W. Baird downgraded Marinus Pharmaceuticals from Outperform to Neutral and set a new price target of $2.00 from $20.00 previously
Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, today announced that they have entered into an agreement and plan of merger under which Immedica has agreed to acquire Marinus, by means of a tender offer and subsequent merger. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241230307666/en/ The acquisition complements and further strengthens Immedica's global rare disease business by adding ZTALMY® (ganaxalone) oral suspension, CV, a neuroactive steroid gamma-aminobuty
ZTALMY® (ganaxolone) Q3 2024 net product revenue of $8.5 million representing growth of 56% versus Q3 2023 Narrowing full year 2024 ZTALMY net product revenue guidance to $33 to $34 million Reported results from Phase 3 TrustTSC trial and commenced process to explore strategic alternatives Marinus continues to support the commercial growth of ZTALMY; further ganaxolone clinical development has been suspended Scheduled to meet with FDA Q4 2024 to discuss a potential path forward for IV ganaxolone in refractory status epilepticus Cost reduction plans implemented with cash runway expected into Q2 2025; cash and cash equivalents of $42.2 million as of September 30, 2024 Marin
Trial did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency (p=0.09); results showed numerically higher response rates for ganaxolone than placebo Ganaxolone was generally well-tolerated in TrustTSC with a safety profile consistent with previous clinical trials Cost reduction activities are underway Marinus has engaged Barclays as an advisor to assist with evaluating strategic alternatives Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Phase 3 TrustTSC trial evaluating oral ganaxolone for the treatment of seizures as
15-12G - MARINUS PHARMACEUTICALS, INC. (0001267813) (Filer)
SCHEDULE 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)
EFFECT - MARINUS PHARMACEUTICALS, INC. (0001267813) (Filer)
4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)
4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)
4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)